Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Area51 who wrote (5663)	1/18/2024 12:51:54 AM
From: Gary Mohilner	Respond to of 5665

I still hope that we either get a better offer, or investors, mostly Institutions turn this down. I really believe that if they waited till after Annual Report was issued both the stock price would have gone higher, and a much higher buyout could have been achieved. As for NWBO, just hold on and add on weakness, like now, and I believe we'll all be very well rewarded. At current prices 200 shares of IMGN will buy 10,000 of NWBO, I don't plan on buying more, but I've said that many times before. I don't know if the UK will grant a tumor agnostic label on the current filing, but I don't believe it will take long to realize that vaccine made from any solid tumor does help to fight that cancer. By itself it's not curative, but with the right therapeutics added it may be. Gary